Retrospective Study
Copyright ©The Author(s) 2025.
World J Diabetes. Apr 15, 2025; 16(4): 102751
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.102751
Table 1 Clinical baseline characteristics of the normotension group, low systolic blood pressure variability group, and high systolic blood pressure variability group
Variables
Normotension group, n = 213
Low SBPV group, n = 334
High SBPV group, n = 334
P value
Baseline characteristic
    Age (years)58.24 ± 9.3261.83 ± 10.19a65.03 ± 10.88a,b< 0.001
    Male sex90 (42.3)164 (49.1)193 (57.8)a,b0.001
    Body mass index (kg/m2)23.71 ± 3.1524.12 ± 3.1324.73 ± 3.99a0.009
    Smoking33 (15.5)57 (17.1)71 (21.2)0.187
    Dyslipidemia94 (44.1)135 (40.4)163(48.8)0.115
    Systolic pressure (mmHg)118 ± 9136 ± 10a149 ± 16a,b< 0.001
    Diastolic pressure (mmHg)73 ± 878 ± 11a85 ± 14a,b< 0.001
Laboratory findings
    Fast glucose (mmol/L)6.68 ± 2.877.66 ± 2.827.72 ± 3.93a,b0.005
    HbA1c (%)7.37 ± 2.367.42 ± 1.86a7.79 ± 1.97a0.027
    Triglyceride (mmol/L)1.36 (0.91, 1.82)1.46 (0.81, 2.11)1.55 (0.68, 2.41)a,b0.001
    Total cholesterol (mmol/L)4.41 ± 1.204.44 ± 1.194.64 ± 1.26a0.004
    HDL-cholesterol (mmol/L)1.25 ± 0.361.26 ± 0.351.28 ± 0.38a,b0.007
    LDL-cholesterol (mmol/L)2.59 ± 0.852.69 ± 0.952.79 ± 0.96a,b< 0.001
Lipid - lowering medication
    Statin128 (60.1)214 (64.1)261 (78.1)a,b0.001
Hypertension treatment
    ARB/ACEI-128 (38.3)82 (24.6)b< 0.001
    Beta - blocker-87 (26.1)65 (19.5)0.064
    Diuretics-27 (8.1)22 (6.6)0.830
    Calcium channel blocker-119 (35.6)163 (48.8)b0.001
Diabetes treatment
    Oral77 (36.1)142 (42.5)183 (54.8)a,b< 0.001
    Insulin36 (16.9)57 (17.1)70 (20.1)0.192
Tube voltage of CT acquisition (kVp)0.002
    100139 (65.3)183 (54.8)152 (45.5)
    12071 (33.4)144 (43.1)158 (47.3)
    1403 (1.4)7 (2.1)24 (7.2)